GROWTH
Top line contracting.
−2.9% YoY versus +2.2% prior. 3y CAGR +0.2%.
−2.9%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
3 of 3 legendary models say BUY OGN.
What would legendary investors pay for OGN?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Organon & Co.'s ROE and debt-to-equity are non-meaningful — large accumulated buybacks have driven stockholders' equity below zero, so the ratio denominators are uninterpretable. Operating margin and free cash flow are the better lenses here.
Financial story
Organon & Co.'s ROE and debt-to-equity are non-meaningful — large accumulated buybacks have driven stockholders' equity below zero, so the ratio denominators are uninterpretable. Operating margin and free cash flow are the better lenses here.
Bottom line: OGN is rated BUY by all 3 legendary models, 72% below avg fair value $47, but earns a C sector grade (46/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
3 of 3 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
OGN's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
OGN is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
3 of 3 legendary investor models rate OGN a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $47. See the per-investor fair-value table in the valuation tab.
OGN trades at 14.3x earnings. Sector context and per-investor signals are in the valuation tab.
How does OGN compare?
See exactly where OGN ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingOGN sits at #72 in Healthcare with a C grade (46/100).
−2.9% YoY versus +2.2% prior. 3y CAGR +0.2%.
−2.9%Net margin 3.0% versus 13.5% prior (−10.5pp). Operating 20.7%.
3.0%P/E 14.4x — 121% above the 5y median of 6.5x. Forward 3.9x hints at EPS expansion next year.
14.4x